Studies a shorter, adaptive radiation treatment for early prostate cancer
Observes side effects and quality of life in men with early prostate cancer.
Plain-language title generated from the registry record
Registry title: Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
Key facts
- Where
- Jena, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 or older with early stage prostate cancer who will have radiotherapy in a few high-dose sessions.
- Age
- 18 Years to 120 Years
- Sex
- Men only
- Disease stage
- Early stage prostate cancer.
- Earlier treatment
- No androgen deprivation therapy (hormone therapy) within the last 2 months before radiotherapy.
Main reasons for not taking part
- Androgen deprivation therapy within the last 2 months before radiotherapy
- A second cancer (secondary malignancy)
- Poor performance status (ECOG above 1)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 120 years old?
Source: NCT06355050, who can take part
Where in Germany
- Department of Radiotherapy and Radiation Oncology, Jena University HospitalJena, GermanyContact: Klaus Pietschmann, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Jena University Hospital
- Trial code
- NCT06355050
- Record updated
- 11 June 2026
- Original description
In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.Read full original descriptionShow less
Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer - Ultra-HART
In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.
Inclusion: no androgen deprivation therapy within the last 2 months prior to RT; good performance status (Eastern Cooperative Oncology Group, ECOG, 0/1); no secondary malignancy.